Harvard Apparatus Regenerative Technology (HRGN) Q3 2024 earnings summary

Executive summary

• Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotech company focused on regenerative medicine for GI tract and airway disorders, and also sells consumer health products, mainly dietary supplements in Asia.

• The company launched its first esophageal implant clinical trial, but faced delays in patient recruitment due to stringent FDA criteria and logistical challenges.

• Consumer Health Products segment began generating revenue in Q3 2023, targeting the Great China Region via eCommerce.

Financial highlights

• Product revenue was $59,000 for Q3 2024, up 48% year-over-year; nine-month revenue was $172,000, up 330% year-over-year.

• Net loss for Q3 2024 was $1.86 million, compared to $1.62 million in Q3 2023; nine-month net loss was $6.39 million, an improvement from $7.12 million in the prior year.

• Gross margin declined due to discounted sales for market penetration.

• Operating expenses for the nine months ended September 30, 2024, were $6.53 million, down 9% year-over-year.

• Cash and cash equivalents were $3.6 million as of September 30, 2024.

Outlook and guidance

• Current cash is expected to fund operations into Q2 2025; additional capital will be required to continue operations beyond that point.

• The company is seeking further financing through equity, debt, grants, or collaborations.